tp53 gene test for hematolymphoid malignancies and multiple myelomas
MedGenome and Fortis Memorial Research Institute cordially invite you to a webinar on
Role of TP53 Gene in Hematolymphoid Malignancies and Multiple Myeloma
Mutations of the TP53 gene and dysregulation of the TP53 pathway are important in the pathogenesis of many human cancers, including leukemias, lymphomas and myelomas. Tumor suppressor p53 protein (cellular tumor antigen p53), is “the guardian of the genome,” preserves genome stability under cellular stress, and is involved in various processes of development, differentiation, aging, and disease.
Dysfunction of p53 in human cancers can result from deletion, mutations, and dysregulation of TP53 gene expression and other p53 related activities. These mechanisms provide multiple ways to inactivate the functions of the TP53 pathway. This opens up a wide spectrum of applications of TP53 gene testing for hematolymphoid malignancies as well as Multiple Myeloma.
Dr. Vidya Veldore
Principal Scientist, Oncology - MedGenome Labs Ltd
Dr. Rahul Bhargava,
Director & HOD – Haematology, Haemato Oncology and BMT, Fortis Memorial Research Institute, Gurugram